CHA₂DS₂-VASc Score

Why use it

Guideline-recommended (ESC, AHA/ACC) for anticoagulation decision-making in atrial fibrillation. Identifies truly low-risk patients who may safely avoid anticoagulation.

About

The CHA₂DS₂-VASc score refines the original CHADS₂ score by incorporating additional stroke risk factors (vascular disease, age 65–74, sex category). It is the guideline-recommended tool for stroke risk assessment in patients with non-valvular atrial fibrillation, guiding decisions on anticoagulation therapy.

When to use

• Non-valvular atrial fibrillation or atrial flutter
• Decision-making regarding oral anticoagulation initiation
• Risk re-stratification during follow-up visits

Formula

Pearls & pitfalls

• Female sex alone (score of 1 in females) does not warrant anticoagulation — it is a risk modifier, not an independent indication.
• The maximum score is 9, not 10, because the age categories are mutually exclusive.
• Vascular disease includes prior MI, peripheral artery disease, and aortic plaque.
• HAS-BLED should be used alongside CHA₂DS₂-VASc — a high bleeding risk rarely justifies withholding anticoagulation.
• DOACs (apixaban, rivaroxaban, edoxaban, dabigatran) are preferred over warfarin for most patients with non-valvular AF.

Next steps

For scores ≥ 2 (males) or ≥ 3 (females), initiate oral anticoagulation (DOAC preferred over warfarin). For score 1 (males) or 2 (females), anticoagulation should be considered. For score 0 (males) or 1 (females with only sex criterion), no antithrombotic therapy recommended. Always assess bleeding risk with HAS-BLED concurrently.

Evidence

Validated in multiple large cohorts (>170,000 patients). ESC 2020 and AHA/ACC/HRS 2019 guidelines recommend CHA₂DS₂-VASc as the primary stroke risk tool in AF. Annualized stroke rates range from ~0% (score 0) to >15% (score 9).

References

1. Lip GYH et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263-272. — link
2. Hindricks G et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. Eur Heart J. 2021;42(5):373-498. — link